Pro-Dex (NASDAQ:PDEX) Releases Earnings Results, Beats Expectations By $0.11 EPS

Pro-Dex (NASDAQ:PDEX) released its earnings results on Thursday. The medical instruments supplier reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.11, Yahoo Finance reports. The company had revenue of $15.03 million during the quarter. Pro-Dex had a return on equity of 6.50% and a net margin of 4.13%.

Pro-Dex Trading Up 4.6 %

Pro-Dex stock traded up $1.03 during mid-day trading on Friday, hitting $23.28. 26,474 shares of the company’s stock were exchanged, compared to its average volume of 8,070. The company’s 50 day simple moving average is $19.73 and its 200-day simple moving average is $18.85. The company has a quick ratio of 2.08, a current ratio of 3.45 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $79.62 million, a P/E ratio of 40.14 and a beta of 0.38. Pro-Dex has a fifty-two week low of $14.51 and a fifty-two week high of $24.74.

Insider Buying and Selling at Pro-Dex

In related news, Director Angelita Rebamontan Domingo sold 2,585 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $18.30, for a total value of $47,305.50. Following the completion of the transaction, the director now directly owns 8,191 shares of the company’s stock, valued at approximately $149,895.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 42.60% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.